PD-1/L1
Delve into the world of PD-1/L1 in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on PD-1/L1 to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B
Sino Biopharmaceutical Limited (HKG: 1177) announced that TQ‑A3334 (a Toll-like receptor 7 agonist) and TQA3605 (a core protein allosteric modulator, CpAM), both Category 1 innovative drugs independently developed by its…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
